Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues
A random biochemical screening followed by lead optimization culminated in the discovery of Ro 40-7592 (3,4-dihydroxy-4′-methyl-5-nitrobenzophenone). Ro 40-7592 was found to inhibit COMT in a competitive fashion both in the CNS and in the periphery (Ki for the liver enzyme = 30 nM). Ro 40-7592 (30 mg/kg p.o.) combined with benserazide (15mg/kg p.o.) and a low dose of L-DOPA (10 mg/kg p.o.) almost completely blocked (for about 6 h) the formation of 3-O-methyldopa (3-OMD) in brain and plasma, producing a long-lasting increase of L-DOPA in plasma and a parallel marked increase of L-DOPA and dopamine in the brain. Ro 40-7592, combined with peripheral decarboxylase inhibitors and L-DOPA (as in Madopar® and Sinemet®), will offer substantial advantages in the therapy of Parkinson’s disease, i.e. enhanced bioavailability and prolonged plasma half-life of L-DOPA, pronounced DOPA sparing effect and blockade of 3-OMD formation.
KeywordsCOMT Inhibition COMT Activity Peripheral Decarboxylase Inhibitor Intact Amino Acid High COMT Activity
Unable to display preview. Download preview PDF.
- Da Prada M, Kettler R, Zürcher G, Schaffner R, Haefely WE (1987) Inhibition of decarboxylase and levels of DOPA and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol 27 [Suppl] 1:9–20.PubMedCrossRefGoogle Scholar
- Da Prada M, Zürcher G, Kettler R, Colzi A (1990) New therapeutic strategies in Parkinson’s disease: inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592. In: Bernardi G, Carpenter M, Di Chiara G, Stanzione P (eds) Proc, 3rd Triennal Meeting “Basal Ganglia 89—. Plenum Press, New York (in press).Google Scholar
- Zürcher G, Da Prada M (1990) A single automated HPLC column-switching technique for the measurement of DOPA and 3-O-methyldopa in plasma. J Chromatogr (Bioch Appl) (in press).Google Scholar